CT26-hSIGLEC15

Export PDF

Strain Information

Validation Data

image.png

Figure 1. Expression of human SIGLEC15 on CT26-hSIGLEC15 cells was confirmed by flow cytometry.  

CT26-hSIGLEC15 cells and wild type CT26 cells were stained with species-specific anti-SIGLEC15 antibody.  FACS analysis shows that human SIGLEC15 expression on CT26-hSIGLEC15 cells was detectable.  Human SIGLEC15 expression of 18# and 28# clones were 52.65% and 93.15%.

image.png

Figure 2. In vivo tumor growth curves in humanized CT26-hSIGLEC15 syngeneic model.

BALB/c mice were subcutaneously injected CT26-hSIGLEC15 cells. Tumor growth was monitored by measuring tumor size from day 14 after subcutaneous implantation.

image.png

Figure 3. FACS analysis of SIGLEC15 expression on tumor cells derived from humanized CT26-hSIGLEC15 syngeneic model with species-specific anti-SIGLEC15 antibodies.  

FACS analysis shows that human SIGLEC15 expression in human SIGLEC15 knock-in tumor were 48.61% (18# clone) and 60.48% (28# clone).


Related Strain(s)

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more